Grappling with the quality of life. Patients, FDA and drug companies struggle to link therapies with well-being.
Lewis
C
C
D000970:Antineoplastic Agents / Q000009:adverse effects; D002243:Carbolines / Q000009:adverse effects; D003109:Colonic Diseases, Functional / Q000188:drug therapy; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects; D006801:Humans; D008297:Male; D011788:Quality of Life
D000970:Antineoplastic Agents; D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron